01 7Linzess
02 8Linzess/Constella
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2020 Revenue in Millions : 667
2019 Revenue in Millions : 0
Growth (%) : 100
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2021 Revenue in Millions : 1,038
2020 Revenue in Millions : 667
Growth (%) : 56
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2022 Revenue in Millions : 1,035
2021 Revenue in Millions : 1,038
Growth (%) : -0.3
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2023 Revenue in Millions : 1,108
2022 Revenue in Millions : 1,035
Growth (%) : 7.1
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2017 Revenue in Millions : 723
2016 Revenue in Millions : 643
Growth (%) : 12
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2018 Revenue in Millions : 785
2017 Revenue in Millions : 723
Growth (%) : 9%
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2016 Revenue in Millions : 643
2015 Revenue in Millions : 459
Growth (%) : 40
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2019 Revenue in Millions : 827
2018 Revenue in Millions : 785
Growth (%) : 5
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2020 Revenue in Millions : 57
2019 Revenue in Millions : 49
Growth (%) : 15
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2021 Revenue in Millions : 58
2020 Revenue in Millions : 56
Growth (%) : 11
LOOKING FOR A SUPPLIER?